Yahoo
NasdaqGM - Nasdaq Real Time Price USD

Silence Therapeutics plc (SLN)

19.66 -0.01 (-0.05%)
At close: 4:00:00 PM EDT
19.65 -0.01 (-0.05%)
After hours: 4:07:44 PM EDT
Trade SLN on Coinbase
Chart Range Bar
Loading chart for SLN
  • Previous Close 19.67
  • Open 19.65
  • Bid 7.92 x 200
  • Ask 14.22 x 200
  • Day's Range 19.62 - 19.68
  • 52 Week Range 4.19 - 19.68
  • Volume 3,078,425
  • Avg. Volume 2,580,423
  • Market Cap (intraday) 1.222B
  • Beta (5Y Monthly) 1.45
  • PE Ratio (TTM) --
  • EPS (TTM) -1.29
  • Earnings Date (est.) Nov 5, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 19.75
  • Zacks Rating Bullish

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.

www.silence-therapeutics.com

88

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 10/22/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

SLN
223.36%
S&P 500 (^GSPC)
11.95%

1-Year Return

SLN
173.06%
S&P 500 (^GSPC)
14.39%

3-Year Return

SLN
175.74%
S&P 500 (^GSPC)
81.42%

5-Year Return

SLN
14.52%
S&P 500 (^GSPC)
68.62%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -9.09M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-15M
-10M
-5M
0
-30000.0%
-20000.0%
-10000.0%
0.0%

Analyst Insights

View More

Analyst Price Targets

19.00 Low
19.75 Average
19.66 Current
20.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/21/2026
Analyst HC Wainwright & Co.
Rating Action Downgrade
Rating Neutral
Price Action Lowers
Price Target 75 -> 20

Statistics

View More

Valuation Measures

Annual
As of 9/23/2026
  • Market Cap

    745.85M

  • Enterprise Value

    673.91M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    884.02

  • Price/Book (mrq)

    18.60

  • Enterprise Value/Revenue

    1.10k

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -29.65%

  • Return on Equity (ttm)

    -90.41%

  • Revenue (ttm)

    615k

  • Net Income Avi to Common (ttm)

    -59.95M

  • Diluted EPS (ttm)

    -1.29

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    72.05M

  • Total Debt/Equity (mrq)

    0.29%

  • Levered Free Cash Flow (ttm)

    -23.57M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

19.66 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: